Paricalcitol

Names

[ CAS No. ]:
131918-61-1

[ Name ]:
Paricalcitol

[Synonym ]:
9,10-secoestra-5,7-diene-1,3-diol, 17-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexenyl]-, (1R,3R,7E,17β)-
(1R,3R)-5-[(2E)-2-{(1R,3aS,7aR)-1-[(1R,2E,4S)-5-hydroxy-1,4,5-triméthylhex-2-én-1-yl]-7a-méthyloctahydro-4H-indén-4-ylidène}éthylidène]cyclohexane-1,3-diol
(1a,3b,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
(1R,3R,7E,17β)-17-[(2R,3E,5S)-6-Hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol
(7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1a,3b,25-triol
1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-
Paracalcin
19-Nor-1a,25-dihydroxyvitamin D2
(1R,3R,7E,17β)-17-[(2R,3E,5S)-6-Hydroxy-5,6-dimethyl-3-hepten-2-yl]-9,10-secoestra-5,7-diene-1,3-diol
(1α,3β,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
Zemplar
(1R,3R)-5-[(2E)-2-{(1R,3aS,7aR)-1-[(1R,2E,4S)-5-Hydroxy-1,4,5-trimethylhex-2-en-1-yl]-7a-methyloctahydro-4H-inden-4-yliden}ethyliden]cyclohexan-1,3-diol
(1R,3R,7E,17β)-17-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethylhex-2-en-1-yl]-9,10-secoestra-5,7-diene-1,3-diol
(1R,3R)-5-[(2E)-2-{(1R,3aS,7aR)-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethylhex-2-en-1-yl]-7a-methyloctahydro-4H-inden-4-ylidene}ethylidene]cyclohexane-1,3-diol
Paricalcitol
19-Nor-1alpha,25-dihydroxyvitamin D2
(1R,3R,7E,17β)-17-[(2R,3E,5S)-6-Hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-dien-1,3-diol
1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R)-

Biological Activity

[Description]:

Paricalcitol is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.

[Related Catalog]:

Signaling Pathways >> Vitamin D Related >> VD/VDR

Research Areas >> Metabolic Disease

[In Vitro]

Paricalcitol (3×10-8 M; HP + PC) produces a significant reduction in calcification relative to the observed in cells in HP medium. Paricalcitol causes a reduction in the levels of nuclear β-catenin to a level similar to that observed in control cells[1].

[In Vivo]

Paricalcitol (300 ng/kg/day) significantly decreases Tau, and prevents LV dysfunction in mice. Paricalcitol reduces mRNA expression of ANP, fibronectin and collagen III in the TAC-pari mice[2].

[Animal admin]

After TAC or sham surgery, a subset of the mice is treated with paricalcitol, a selective vitamin D receptor activator, which activates the VDR, at a final dose of 300 ng/kg/day. Paricalcitol is dissolved in a 95% propylene glycol and 5% ethyl alcohol solution. Mice are intraperitoneally injected with paricalcitol (or vehicle only) three times per week on Monday, Wednesday and Friday for five consecutive weeks. An established anti-hypertrophic and anti-fibrotic treatment, namely the angiotensin II receptor blocker (ARB) losartan is also included. Previous experiments have shown it is feasible and efficacious to dissolve losartan in the drinking water at a concentration of 30 mg/kg/day; mice are treated for five consecutive weeks. So, in total eight groups are studied. Sham (n=10), TAC (n=10), Sham + losartan (Sham-los, n=10), TAC + losartan (TAC-los, n=10), Sham + paricalcitol (Sham-pari, n=10), TAC + paricalcitol (TAC-pari, n=10), Sham + paricalcitol + losartan (Sham-combi, n=10) and TAC + paricalcitol + losartan (TAC-combi, n=10).

[References]

[1]. Martinez-Moreno JM, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation. Am J Physiol Renal Physiol. 2012 Aug 8.

[2]. Meems LM, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012 Jul 16;132(3-5):282-289.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.1±0.1 g/cm3

[ Boiling Point ]:
564.8±50.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₇H₄₄O₃

[ Molecular Weight ]:
416.637

[ Flash Point ]:
238.3±24.7 °C

[ Exact Mass ]:
416.329041

[ PSA ]:
60.69000

[ LogP ]:
5.83

[ Vapour Pressure ]:
0.0±3.5 mmHg at 25°C

[ Index of Refraction ]:
1.609

[ Storage condition ]:
-20°C

Safety Information

[ Symbol ]:

GHS06, GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301 + H311-H330-H372

[ Precautionary Statements ]:
Missing Phrase - N15.00950417-P260-P280-P302 + P352 + P312-P304 + P340 + P310-P403 + P233

[ RIDADR ]:
UN 2811 6.1 / PGI

Articles

Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids.

Reprod. Sci. 21(9) , 1108-19, (2014)

We examined the antitumor and therapeutic potentials of paricalcitol, an analog of 1,25-dihydroxyvitamin D3 with lower calcemic activity, against uterine fibroids using in vitro and in vivo evaluation...

Mesenchymal stem cells and a vitamin D receptor agonist additively suppress T helper 17 cells and the related inflammatory response in the kidney.

Am. J. Physiol. Renal Physiol. 307(12) , F1412-26, (2014)

Mesenchymal stem cells (MSCs) suppress T helper (Th)17 cell differentiation and are being clinically pursued for conditions associated with aberrant Th17 responses. Whether such immunomodulatory effec...

Spotlight on paricalcitol in secondary hyperparathyroidism.

Treat. Endocrinol. 4(3) , 185-6, (2005)

Paricalcitol (Zemplar) is a synthetic vitamin D2 analog that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most Europea...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.